COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00750256
Recruitment Status : Completed
First Posted : September 10, 2008
Last Update Posted : July 21, 2017
Information provided by (Responsible Party):

Brief Summary:
A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects

Condition or disease Intervention/treatment Phase
Anaemia Drug: GSK1278863A Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects
Actual Study Start Date : July 7, 2008
Actual Primary Completion Date : December 12, 2008
Actual Study Completion Date : December 12, 2008

Arm Intervention/treatment
Experimental: Cohorts
This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
Drug: GSK1278863A
GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.

Primary Outcome Measures :
  1. GSK1278863A safety endpoints: adverse events reporting, clinical safety laboratory tests (hematology, chemistry, urinalysis,and fecal occult blood), vital signs, 12-lead ECG, dual-lead cardiac monitoring. [ Time Frame: 1 Day ]

Secondary Outcome Measures :
  1. Blood and urine levels of GSK1278863A [ Time Frame: 2 Days ]
  2. Effect of GSK1278863A on hematological markers [ Time Frame: 2 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, non-smoking (within 40 days of screening), adult males and females between 18 and 55 years of age, inclusive
  • Female subjects are eligible for participation in the study if they are of:
  • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant);
  • Male subjects agree to use contraception methods
  • Body weight > or = 50 kg; BMI: 19-31 kg/m2, inclusive
  • Subject has a QTc <450 msec or <480 msec if associated with bundle branch block
  • Subject is willing and able to provide written informed consent

Exclusion Criteria:

  • MCV value outside the reference range at screening
  • Hemoglobin value at screening is: male subjects or post-menopausal females > 15.5 g/dL; female subjects > 14.5 g/dL
  • TIBC, serum iron and serum ferritin values are outside the reference range at screening
  • Calculated creatinine clearance < 60 ml/min
  • Clinically significant abnormal CPK determined by the investigator and medical monitor
  • AST, ALT and direct bilirubin are greater than upper limit of reference range at screening
  • Subjects are unwilling or inability to follow the procedures and lifestyle and/or dietary restrictions outlined in the protocol
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor this will not interfere with the study procedures or compromise subject safety
  • Subject currently exposures to more than four new chemical entities within 12 months prior to the first dosing day
  • Use of other prescription or non-prescription drugs, vitamins, herbal and dietary supplements, within 7 days prior to the first dose of study medication
  • Subject has a history of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
  • Subject has a history of GI ulceration or gastrointestinal bleeding
  • Subject has a history of peptic ulcer disease
  • Subject has a history of malignancy tumor; non-melanoma skin cancer that has been definitely removed is allowed
  • Treatment with an investigational drug within 30 days preceding the first dose of study medication
  • Subjects with a history of drug abuse
  • History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
  • Positive urine drug screen (UDS) at screening
  • Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result or positive HIV result within 3 months of screening
  • Donation of blood in excess of 500 mL within 56 days prior to first dose of study medication
  • Subject has a history of regular use of tobacco- or nicotine containing products
  • History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to any of the study medications or components thereof

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00750256

Layout table for location information
United States, Indiana
GSK Investigational Site
Evansville, Indiana, United States, 47710
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT00750256    
Other Study ID Numbers: PHX111427
First Posted: September 10, 2008    Key Record Dates
Last Update Posted: July 21, 2017
Last Verified: July 2017
Keywords provided by GlaxoSmithKline: